India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
XLV•Analysts say the impact is still uncertain
"The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term
Indian pharma stocks decline after tariff comments
Nifty Pharma Index .NIPHARM down 1.52%
Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
Trump outlines phased tariffs on imported generic drugs
Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
